Bristol Myers Squibb Recommends Stockholders Reject “Mini-Tender” Offer by Tutanota LLCBusiness Wire • 02/14/24
KARUNA THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Karuna Therapeutics, Inc. - KRTXBusiness Wire • 02/14/24
U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Augtyro™ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid TumorsBusiness Wire • 02/14/24
VantAI Enters Collaboration With Bristol Myers Squibb to Accelerate Molecular Glue Drug Discovery Through Artificial IntelligenceBusiness Wire • 02/13/24
Bristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting PeriodBusiness Wire • 02/12/24
J&J, Merck and Bristol Myers CEOs, under fire on Capitol Hill, seek to turn up heat on drug-market middlemenMarket Watch • 02/08/24
Pharma CEOs Will Testify Today Over Prescription Drug Prices: Here's What To Watch ForForbes • 02/08/24
Senators to question Merck, J&J and Bristol Myers Squibb CEOs over high U.S. drug pricingCNBC • 02/08/24
Merck, J&J and Bristol Myers CEOs face drug-pricing grilling on Capitol Hill, but experts cite deeper problems under the radarMarket Watch • 02/07/24
Bristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung CancerBusiness Wire • 02/07/24
Bristol Myers Squibb Named One of America's Most JUST Companies by JUST Capital and CNBCBusiness Wire • 02/05/24
Bristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 StudyBusiness Wire • 02/05/24